Colorectal Carcinoma-targeting Adenovirus Vector Construction Service
Colorectal carcinoma (CRC) is the third most common malignancies in the United States. In China, CRC is the second and fourth leading cause of cancer death in men and women, respectively. Gene therapy as a highly innovative method has become a research hotspot for CRC treatment. Adenovirus vector-mediated gene therapy has achieved a positive effect in preclinical studies. Creative Biolabs is a leading provider of biotechnology services and has developed excellent adenovirus vector construction platforms related to gene therapy. We provide a variety of targeted adenovirus vectors to meet the diverse needs of our customers.
Introduction of Colorectal Carcinoma-targeting Adenovirus Vector
Gene-replacement therapy would involve the use of adenovirus vectors to reintroduce wild-type genes for phenotypic correction. Common mutations in CRC, such as those of the tumor suppressor p53 (45-60% of CRC cases) or the proto-oncogene KRAS (50-60%), have been assessed as therapeutic targets. Wild type p53 has been shown to be involved in transcriptional regulation, cell cycle arrest at the G1/S checkpoint, and induction of apoptosis. The p53 gene has clearly been shown to be the most commonly mutated oncogene in CRC. There are in vitro and in vivo data showing that exposure of CRC cells to recombinant adenovirus encoding wild-type p53 has a definite antiproliferative effect and can suppress cell transformation and neoplastic cell growth. KRAS has an important role in maintaining the uncontrolled proliferation that is characteristic of CRC. Besides, scientists developed a rat model of liver metastasis using a KRAS-mutated CRC cell line and showed that significant tumor regression occurred after hepatic arterial administration of a replication-deficient adenovirus encoding an intracellular antibody specific for KRAS.
Figure 1. Gene therapy using an adenovirus vector.
Service
CRC lends itself to various gene-therapy approaches, which include gene correction or replacement, virus-directed enzyme-prodrug therapy, immunogenetic manipulation and virotherapy. Adenovirus vectors offered the promise of highly efficient in vivo gene delivery. Creative Biolabs offers a variety of adenovirus vector construction services, including adenoviral transduction of CRC cells with the gene encoding interleukin-2, p53, and KRAS. We successfully produced an E1B-deficient adenovirus vector that preferentially replicates in cancer cells with mutated or deleted p53.
Creative Biolabs has focused on the development of gene therapies for years, we are committed to working with you to accomplish our shared goals. We have accumulated a wealth of scientific experience from completed projects and are very proud of our high-quality adenovirus vector construction services to ensure your requirements are met. If you are interested in our services, please contact us for more details.
